Personalized immunotherapy for the treat
β
Julie M Vose
π
Article
π
2006
π
John Wiley and Sons
π
English
β 174 KB
The efficacy of immunotherapeutic strategies for the treatment of lymphoid malignancies has been demonstrated in recent years. In patients with B-cell lymphomas, particularly indolent lymphoma, the use of passive immunotherapy, such as the anti-CD20 monoclonal antibody rituximab, has made an impress